<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066518</url>
  </required_header>
  <id_info>
    <org_study_id>GE15-002</org_study_id>
    <nct_id>NCT03066518</nct_id>
  </id_info>
  <brief_title>Effect of Melatonin on Sleep Quality in Patients Dementia</brief_title>
  <official_title>A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Patients with dementia may suffer from poor sleep quality. Disturbance in the
      metabolism melatonin may have a role in the pathogenesis of sleep-wake cycle alterations in
      dementia.

      Objective: To evaluate the efficacy of low dose exogenous melatonin in improving sleep
      quality.

      Design: A single-center randomized, double-blinded, placebo-controlled study carried out on
      outpatients with dementia and sleep alterations.

      Participants: The investigators calculated a 40 individuals aged 65 years or over with a
      diagnosis of mild-moderate dementia (Clinical Dementia Rating 1-2).

      Intervention: Patients were randomized to receive either 5 mg of melatonin or placebo every
      night for 8 weeks.

      Measurements: The primary outcome was sleep quality according to the Pittsburgh Sleep Quality
      Index (PSQI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center study. The study protocol, informed consents, and amendments were
      approved in writing by the appropriate local site Independent Ethics Committee
      (IEC)/Institutional Review Boards (IRB) (Ethics Committee of the Universidad Autónoma de
      Nuevo León, School of Medicine).

      The patients were recruited as outpatients from the Geriatrics Clinic. A total of 67 patients
      were screened out of which 40 male and female patients diagnosed with mild to moderate
      dementia were recruited to the study. Following inclusion, all patients underwent
      randomization to treatment with melatonin (5 mg orally) or placebo for 8 weeks. To prevent
      bias, matching placebo tablets, which were identical in appearance, taste, and odor, were
      used. The treatment was double-blinded, with two parallel treatment groups. Selection for a
      treatment group was determined by a computer-generated randomization list, in a 1:1 ratio
      using the randomized permuted blocks method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Actual">January 25, 2017</completion_date>
  <primary_completion_date type="Actual">January 25, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blinded, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>8 weeks</time_frame>
    <description>A self-administered questionnaire that provides an overall rating of sleep quality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimental test</measure>
    <time_frame>baseline and to the 8 weeks</time_frame>
    <description>The original purpose is to allow physicians to standardize and quantify cognitive status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sleep Disorders</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Melatonin 5 mg, daily, eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, daily, eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 5 mg</intervention_name>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Benedorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 60 years;

          -  Circadian cycle sleep disorder with insomnia (according to Diagnostic and Statistical
             Manual of Mental Disorders- V criteria);

          -  Mild or moderate dementia (clinical dementia rating 1 and 2);

          -  Medications such as anti-depressants, acetylcholinesterase inhibitors, antipsychotics
             or memantine were allowed as long as they were initiated for over 8 weeks.

        Exclusion Criteria:

          -  They had other diagnoses of sleep disorders, known hypersensitivity to melatonin, use
             of stimulants or hypnotics, recent diagnosis (within 8 weeks) of mood disorders or
             neuropsychiatric symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Guajardo, MD</last_name>
    <role>Study Director</role>
    <affiliation>HUGonzález</affiliation>
  </overall_official>
  <reference>
    <citation>Crowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011 Mar;21(1):41-53. doi: 10.1007/s11065-010-9154-6. Epub 2011 Jan 12. Review.</citation>
    <PMID>21225347</PMID>
  </reference>
  <reference>
    <citation>Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181-9. doi: 10.1159/000236900. Epub 2009 Sep 9. Review.</citation>
    <PMID>19738366</PMID>
  </reference>
  <reference>
    <citation>Beaulieu-Bonneau S, Hudon C. Sleep disturbances in older adults with mild cognitive impairment. Int Psychogeriatr. 2009 Aug;21(4):654-66. doi: 10.1017/S1041610209009120. Epub 2009 May 11. Review.</citation>
    <PMID>19426575</PMID>
  </reference>
  <reference>
    <citation>Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs. 2011 Oct;4(4):281-93. doi: 10.3928/19404921-20110302-01. Epub 2011 Mar 16.</citation>
    <PMID>21417189</PMID>
  </reference>
  <reference>
    <citation>Guarnieri B, Cerroni G, Sorbi S. Sleep disturbances and cognitive decline: recommendations on clinical assessment and the management. Arch Ital Biol. 2015 Jun-Sep;153(2-3):225-30. doi: 10.12871/0003982920152347.</citation>
    <PMID>26742676</PMID>
  </reference>
  <reference>
    <citation>Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol. 2016 Sep;18(9):40. doi: 10.1007/s11940-016-0424-3. Review.</citation>
    <PMID>27476067</PMID>
  </reference>
  <reference>
    <citation>Xu J, Wang LL, Dammer EB, Li CB, Xu G, Chen SD, Wang G. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):439-47. doi: 10.1177/1533317514568005. Review.</citation>
    <PMID>25614508</PMID>
  </reference>
  <reference>
    <citation>McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016 Nov 16;11:CD009178. Review.</citation>
    <PMID>27851868</PMID>
  </reference>
  <reference>
    <citation>Chien MY, Chen HC. Poor sleep quality is independently associated with physical disability in older adults. J Clin Sleep Med. 2015 Mar 15;11(3):225-32. doi: 10.5664/jcsm.4532.</citation>
    <PMID>25515275</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Rocio Morales Delgado</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>sleep</keyword>
  <keyword>dementia</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

